WO2000024387A3 - A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid - Google Patents

A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid Download PDF

Info

Publication number
WO2000024387A3
WO2000024387A3 PCT/CA1999/000994 CA9900994W WO0024387A3 WO 2000024387 A3 WO2000024387 A3 WO 2000024387A3 CA 9900994 W CA9900994 W CA 9900994W WO 0024387 A3 WO0024387 A3 WO 0024387A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
reducing
hyaluronic acid
treating radiation
radiation cystitis
Prior art date
Application number
PCT/CA1999/000994
Other languages
French (fr)
Other versions
WO2000024387A2 (en
Inventor
Peter J Pommerville
Original Assignee
Bioniche Inc
Peter J Pommerville
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Inc, Peter J Pommerville filed Critical Bioniche Inc
Priority to US09/830,063 priority Critical patent/US6667296B1/en
Priority to AU64558/99A priority patent/AU761158B2/en
Priority to DE69916643T priority patent/DE69916643T2/en
Priority to NZ511068A priority patent/NZ511068A/en
Priority to JP2000577997A priority patent/JP4685242B2/en
Priority to CA002347110A priority patent/CA2347110C/en
Priority to EP99952186A priority patent/EP1124546B1/en
Priority to AT99952186T priority patent/ATE264674T1/en
Publication of WO2000024387A2 publication Critical patent/WO2000024387A2/en
Publication of WO2000024387A3 publication Critical patent/WO2000024387A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for preventing, reducing or treating radiation cystitis caused by external beam radiation therapy, which impinges on the urinary bladder and associated structures, comprising administering into the urinary bladder and associated structures a composition comprising hyaluronic acid (HA) having an average molecular weight of not less than 2 X 105 Daltons and a pharmaceutically acceptable carrier.
PCT/CA1999/000994 1998-10-22 1999-10-22 A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid WO2000024387A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US09/830,063 US6667296B1 (en) 1998-10-22 1999-10-22 Method for preventing and reducing radiation cystitis using hyaluronic acid
AU64558/99A AU761158B2 (en) 1998-10-22 1999-10-22 A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid
DE69916643T DE69916643T2 (en) 1998-10-22 1999-10-22 USE OF HYALURONIC ACID FOR TREATMENT OF IRRADIATED BLOWN IGNITION
NZ511068A NZ511068A (en) 1998-10-22 1999-10-22 Use of hyaluronic acid for preventing, reducing, and treating radiation cystitis
JP2000577997A JP4685242B2 (en) 1998-10-22 1999-10-22 Prevention, reduction, and treatment of radiation cystitis using hyaluronic acid
CA002347110A CA2347110C (en) 1998-10-22 1999-10-22 A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid
EP99952186A EP1124546B1 (en) 1998-10-22 1999-10-22 Use of hyaluronic acid for the treatment of radiation cystitis
AT99952186T ATE264674T1 (en) 1998-10-22 1999-10-22 USE OF HYALURONIC ACID TO TREAT RADIATION BLIDDER INFLAMMATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10518498P 1998-10-22 1998-10-22
US60/105,184 1998-10-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/830,063 A-371-Of-International US6667296B1 (en) 1998-10-22 1999-10-22 Method for preventing and reducing radiation cystitis using hyaluronic acid
US10/705,255 Continuation US20040152662A1 (en) 1998-10-22 2003-11-10 Method for preventing, reducing, and treating radiation cystitis using hyaluronic acid

Publications (2)

Publication Number Publication Date
WO2000024387A2 WO2000024387A2 (en) 2000-05-04
WO2000024387A3 true WO2000024387A3 (en) 2000-08-03

Family

ID=22304511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000994 WO2000024387A2 (en) 1998-10-22 1999-10-22 A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid

Country Status (12)

Country Link
US (2) US6667296B1 (en)
EP (1) EP1124546B1 (en)
JP (1) JP4685242B2 (en)
AT (1) ATE264674T1 (en)
AU (1) AU761158B2 (en)
CA (1) CA2347110C (en)
DE (1) DE69916643T2 (en)
DK (1) DK1124546T3 (en)
ES (1) ES2219070T3 (en)
NZ (1) NZ511068A (en)
PT (1) PT1124546E (en)
WO (1) WO2000024387A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9906619D0 (en) † 1999-03-23 1999-05-19 Zeneca Resins Bv Compositions
WO2005058235A2 (en) * 2003-12-10 2005-06-30 Keryx Biopharmaceuticals, Inc. Methods using sulodexide for the treatment of bladder disease
JP2007233949A (en) * 2006-03-03 2007-09-13 Kyoto Univ Urination management system
ITMI20061030A1 (en) 2006-05-26 2007-11-27 Altergon Sa NEW COMPOSITION INCLUDING GLYCOSAMINOGLICANS WITH CONTROLLED VISCOSITY AND USE OF SUCH COMPOSITION IN THE THERAPY OF CHRONIC CYSTITIS
DE102006060953A1 (en) 2006-12-12 2008-08-07 Farco-Pharma Gmbh Synergistic preparation for treating urinary tract inflammation, e.g. cystitis, contains low molecular hyaluronic acid and another glycosaminoglycan, preferably chondroitin sulfate
HUP0900717A3 (en) * 2009-11-18 2012-02-28 Richter Gedeon Nyrt Pharmaceutical composition for urological use containing zinc hyaluronate
EP3960215A1 (en) 2009-12-15 2022-03-02 Incept, LLC Implants and biodegradable fiducial markers
RU2557949C1 (en) * 2014-08-14 2015-07-27 Общество с ограниченной ответственностью "КОЛЕТЕКС" Method of treating radiation and interstitial cystitis
WO2016146573A1 (en) * 2015-03-13 2016-09-22 Repoceuticals Aps Melatonin for preventing and treating radiation cystitis
RU2676431C1 (en) * 2018-02-26 2018-12-28 Федеральное государственное бюджетное учреждение "Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова" Министерства здравоохранения Российской Федерации (ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России) Radiation cystitis modeling method
WO2019236453A1 (en) * 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025168A1 (en) * 1995-02-14 1996-08-22 Bioniche Inc. Use of hyaluronic acid for the treatment of interstitial cystitis
WO1997003699A1 (en) * 1995-07-18 1997-02-06 Hyal Pharmaceutical Corporation Use of hyaluronic acid and a nsaid for the manufacture of a medicament for the treatment of mucosal diseases
CA2247389A1 (en) * 1996-12-27 1998-07-09 Seikagaku Corporation Agent for treatment of bladder troubles
US5880108A (en) * 1995-02-14 1999-03-09 Bioniche, Inc. Method for treating the internal urinary bladder and associated structures using hyaluronic acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025168A1 (en) * 1995-02-14 1996-08-22 Bioniche Inc. Use of hyaluronic acid for the treatment of interstitial cystitis
US5880108A (en) * 1995-02-14 1999-03-09 Bioniche, Inc. Method for treating the internal urinary bladder and associated structures using hyaluronic acid
WO1997003699A1 (en) * 1995-07-18 1997-02-06 Hyal Pharmaceutical Corporation Use of hyaluronic acid and a nsaid for the manufacture of a medicament for the treatment of mucosal diseases
CA2247389A1 (en) * 1996-12-27 1998-07-09 Seikagaku Corporation Agent for treatment of bladder troubles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DOWNEY JOE; NICKEL J CURTIS; MORALES ALVARO; EMERSON LAUREL; CLARK JANET: "Relative efficacy of various exogenous glycosaminoglycans in providing a bladder surface permeability barrier.", JOURNAL OF UROLOGY, vol. 157, no. 4 Suppl., 1997, pages 128, XP000908840 *
LIGUORI VINCENZO; GUILLEMIN CLAIRE; PESCE GIAN F; MIRIMANOFF RENE O; BERNIER JACQUES: "Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy.", RADIOTHERAPY AND ONCOLOGY, vol. 42, no. 2, 1997, pages 155 - 161, XP000908841 *
PORRU DANIELE; CAMPUS GIULIANA; TUDINO DONATELLA; VALDES ENRICO; VESPA ALESSANDRO; SCARPA ROBERTO M; USAI ENZO: "Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid.", UROLOGIA INTERNATIONALIS, vol. 59, no. 1, 1997, pages 26 - 29, XP000908835 *
STROHMAIER W.L.: "Therapie der Interstitiellen Bzm. Radiogenen Zystitis mit D Glukosamin", HEL. CHIR. ACTA, vol. 56, 1989, pages 323 - 325, XP000908833 *

Also Published As

Publication number Publication date
CA2347110C (en) 2008-08-26
DK1124546T3 (en) 2004-08-09
US20040152662A1 (en) 2004-08-05
NZ511068A (en) 2003-10-31
PT1124546E (en) 2004-08-31
ATE264674T1 (en) 2004-05-15
ES2219070T3 (en) 2004-11-16
AU761158B2 (en) 2003-05-29
JP4685242B2 (en) 2011-05-18
DE69916643T2 (en) 2005-04-28
AU6455899A (en) 2000-05-15
EP1124546A2 (en) 2001-08-22
JP2002528410A (en) 2002-09-03
CA2347110A1 (en) 2000-05-04
WO2000024387A2 (en) 2000-05-04
US6667296B1 (en) 2003-12-23
EP1124546B1 (en) 2004-04-21
DE69916643D1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
WO1997007833A3 (en) Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives
AU5259793A (en) Antiallergic composition for opthalmic or nasal use
CA2255637A1 (en) Conjugates of cis-docosahexaenoic acid and paclitaxel
WO2000024387A3 (en) A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid
ES2127997T3 (en) HIGHLY ACTIVE DOUBLE METALLIC CYANIDE CATALYST.
MY127946A (en) Therapeutic formulation for administering tolterodine with controlled release
CA2263561A1 (en) Thienopyrimidines
WO2002076499A3 (en) Combination treatment of pancreatic cancer
EP0963757A3 (en) Hemostatic agent
CA2118219A1 (en) Preparations of low molecular weight hyaluronic acid for stimulating bone formation
CA2198535A1 (en) Method of increasing testosterone
EP2075002A3 (en) Use of myoblasts in the manufacture of a medicament for treating stress urinary incontinence
EP0635298A3 (en) Catalyst and method for the removal of nitrogen oxides
EP1226809A4 (en) Skin texture-improving agents
EP0292220A3 (en) Condom
WO1999038532A3 (en) Methods for the prevention and treatment of fibrosis and sclerosis
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection
CA2137595A1 (en) Treating hormone-dependent conditions
WO2004008286A3 (en) Arrangements and methods for treating a subject
CA2245540A1 (en) Dual-curing coating formulation and method
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
BR9915431A (en) Cathodic electrocoating coating composition
EP0400219A3 (en) Use of creosote as an antispasmodic agent
WO2001074401A3 (en) Camptothecin complexes
WO2000047197A3 (en) Alkylating agents for treatment of cellular proliferation

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 1999 64558

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 511068

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2347110

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999952186

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 577997

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 64558/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09830063

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999952186

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 64558/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999952186

Country of ref document: EP